Securities code: Sirio Pharma Co.Ltd(300791) securities abbreviation: Sirio Pharma Co.Ltd(300791) Announcement No.: 2022016 securities code: 123113 securities abbreviation: xianle convertible bonds
Sirio Pharma Co.Ltd(300791) 2021 annual report summary
1、 Important tips
The summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC.
All directors personally attended the meeting of the board of directors to consider this annual report
The audit opinion of Huaxing Certified Public Accountants (special general partnership) on the company’s financial report this year is: standard unqualified opinion.
Tips on non-standard audit opinions
□ applicable √ not applicable
The profit distribution plan of ordinary shares or the plan of converting accumulation fund into share capital in the reporting period considered by the board of directors
√ applicable □ not applicable
The company’s profit distribution plan approved by the board of directors is: take 180169870 shares as the base, distribute cash dividends of 4 yuan (including tax) to all shareholders for every 10 shares, do not give bonus shares, and do not use the accumulation fund to increase the share capital. 2、 Basic information of the company 1. Company profile
Stock abbreviation Sirio Pharma Co.Ltd(300791) stock code Sirio Pharma Co.Ltd(300791)
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Zheng Liqun, Chen Annie
Office address: No. 83, Taishan Road, Shantou City, Guangdong Province
Fax: 075488810300
Tel: 075489983800075489983800
E-mail [email protected]. [email protected].
2. Introduction to main business or products during the reporting period
(1) Business profile of the company: Based on market insight, establish product innovation platform and transnational supply platform to serve global brand customers
The company is one of the large contract manufacturers of nutritious and healthy food in China. It provides customers with nutritious and healthy food and services with scientific basis based on the contract R & D and production mode (cdmo). As a global enterprise, the company has established production bases and marketing centers in China, Germany and the United States. Relying on the cutting-edge consumer insight, business information integration mechanism and upstream supplier support in the domestic and foreign markets, the company has formed the advantage of transnational market insight. On the basis of market insight, the company has established a product innovation platform and global supply chain through resource accumulation and investment, innovation and sound management mechanism, With the business model of “strong manufacturing platform + leading new product layout + efficient service”, we provide products that consumers like and need through cooperation with customers, serve global brand customers, realize extensive customer coverage, establish in-depth product cooperation with many excellent enterprises around the world, and actively support the development and growth of some fast-growing cutting-edge brands.
(2) Main products: rich multi dosage form functional product line
According to the classification of product form, the company’s products mainly include soft capsules, tablets, powders, soft candy, drinks, hard capsules, etc.
Rich packaging forms and specifications make the products have a good appearance and meet the diversified needs of customers. The company is equipped with a special marketing team and technology R & D team to continuously carry out research and innovation of dosage form technology, so that consumers can have a better and more convenient eating experience.
According to the functional classification, the company has established multiple product function platforms, such as health function improvement, women’s beautiful health, substitute meals, maternal and infant health, mineral basic nutrition, sports nutrition, probiotics and functional snacks. Led by the doctoral team, the company has carried out scientific formula research, and accordingly developed a multi population and full coverage functional product line, which can meet the needs of infants, children, adolescents Different health needs of different groups from adults to middle-aged and elderly people. (3) Industry position of the company
Focusing on the b-end business of nutrition and health food, the company provides customers with one-stop services from product line planning, product formula development and upgrading, product registration support, product production and packaging, product delivery and marketing support. While maintaining the existing advantages of health food, the company actively expands the field of functional food and healthy snacks. It is the first listed company in China to focus on the b-end business of nutrition and health food, It has strong influence and popularity in the b-end market.
The company has focused on the field of nutrition and health food for more than 20 years, adhered to deeply tap the global market demand and innovative business model, continuously improved the application innovation ability and raw material research ability, always preferred raw materials, always adhered to international high-quality standards, constantly accelerated the response speed to global customers, and actively explored the content of providing value-added services for customers. The company’s customers are mainly distributed in China, Europe and North America, covering pharmaceutical enterprises, direct selling enterprises, non direct selling brand companies, chain pharmacies, modern supermarkets, as well as the head enterprises of different types and business models, such as social e-commerce, food and cosmetics enterprises, which expand new business in the field of nutrition and health. These enterprises together constitute the company’s stable and high viscosity customer base. Through in-depth research on various dosage forms, the company hopes to obtain a more stable, efficient, convenient and comfortable product experience. By the end of the reporting period, the company had two R & D platforms, namely “Guangdong International Engineering Technology Research Center for nutrition and health food” and “Guangdong enterprise technology center”, and set up “Guangdong doctoral workstation”. The company has the ability to quickly and efficiently convert R & D achievements into products and promote them to the market. At present, there are more than 4000 mature nutritional and health food product formulas, which can meet the diversified health needs of different people in the whole life cycle from infants and children, adolescents, adults to the middle-aged and elderly, as well as the health needs of pregnant women and other special groups. The company continues to launch innovative varieties every year to meet customer needs and fill the market gap.
(4) Main performance drivers during the reporting period
In 2021, focusing on the vision of “becoming an innovative leader in the field of nutrition and health and the first choice of customers”, the company went deep into the cdmo field of nutrition and health food (b-end market), and its performance increased steadily.
During the reporting period, the company achieved an operating revenue of 2.369 billion yuan, a year-on-year increase of 14.62%; The net profit attributable to shareholders of listed companies was 232 million yuan, a year-on-year decrease of 9.92%. The net profit after deducting non-profit was 210 million yuan, a year-on-year decrease of 5.61%. Excluding the impact of convertible bond interest and equity payment, the net profit after deducting non profits increased by 3.10% year-on-year. Among the main businesses, domestic businesses achieved a sales revenue of 1.458 billion yuan, a year-on-year increase of 14.06%; Overseas business achieved sales revenue of 911 million yuan, a year-on-year increase of 15.60%.
In 2021, the company’s key work is as follows:
(1) Continue technological innovation and R & D investment, and reserve technology for the future
In the first half of 2021, the company continued to focus on the research and development of preparation technology, efficacy materials, core formula and efficacy verification. During the reporting period, the company invested 831903 million yuan in R & D, a year-on-year increase of 28.56%. Benefiting from early reserves and continuous research and development, the company submitted 35 applications for invention patents, and completed several new product research and development and listing, including new products such as record making gel candy, essence tube drinks, and explosion beads. At the same time, the company continues to carry out exploratory cooperative R & D projects with Guangdong Israel University of technology, South China University of technology and other universities around the raw materials and efficacy of nutritious and healthy food, and reserve technology for the future.
(2) Actively promote the construction of new production capacity projects, expand the scale of production capacity and enhance the layout of industrial chain
During the reporting period, the second nutritional fudge production line of Ma’anshan production base was put into operation in the first quarter of 2021, with an annual production capacity of 800 million tablets. The third nutritional soft candy production line of Ma’anshan production base originally planned to be put into operation in the fourth quarter of 2021 has an annual production capacity of 1.8 billion tablets. Due to the epidemic, overseas equipment suppliers cannot go to the site for installation and commissioning, and the overall progress has been delayed. It is expected to be put into use in the second quarter of 2022.
During the reporting period, the beverage workshop of phase II project of Ma’anshan production base was put into use, integrating the original bagged beverage production line and the bagged beverage production line of Shantou production base, realizing the unified intelligent management of the beverage production line. In the third quarter, Ma’anshan beverage workshop added three production lines, including two bagged beverage production lines, with an annual production capacity of 100 million bags; And a jelly production line with an annual production capacity of 80 million bags.
During the reporting period, Shantou production base added a bead blasting production line with an annual production capacity of 900 million beads; A new production line of essence bottle is added, with an annual capacity of 37 million bottles.
(3) Improve operation efficiency through intelligent manufacturing, lean operation and supply chain optimization
The digital factory project based on lean, intelligent and automation is advancing steadily. The company has established a special equipment engineering and automation department to cooperate with lean operation Department and intelligent manufacturing department to jointly promote the construction of digital factory, aiming to organically integrate order demand with material supply, production and manufacturing, warehousing and logistics and market distribution through big data integration and interconnection, A supply chain management data ecosystem has been formed to improve the ability of rapid response.
(4) Build a customer-oriented self driven organization
The company carried out the transformation and upgrading of organizational structure, strengthened product innovation on the premise of in-depth insight into market demand, created a customer-centered management model, focused internal resources on the front end, and repositioned all departments, released potential and stimulated organizational vitality by dividing small business units. The organizational structure of the company is divided into three modules: Front Office business unit, middle office capability center and back office functional department. The business unit is composed of six business units, which can quickly respond to market demand according to the channel strategy of multi-channel coverage. The capability center includes R & D center, category planning center and global supply chain, which are uniformly managed by the headquarters and play a global synergy; Back office functional departments provide professional consulting and services for business development. 3. Main accounting data and financial indicators (1) whether the company needs to retroactively adjust or restate the accounting data of previous years in recent three years □ yes √ no
Unit: Yuan
Year end 2021 year end 2020 year end increase or decrease over the previous year year end 2019 year end
Total assets 382011017019264963669393 44.17% 235903156044
Net assets attributable to shareholders of listed companies 254477970622218268727564 16.59% 194502302765
20212020 year-on-year increase or decrease 2019
Operating income 236894761687206681776570 14.62% 157956225923
Net profit attributable to shareholders of listed companies 231834489 Beijing Spc Environment Protection Tech Co.Ltd(002573) 6601536 – 9.92% 142525197
Deduction attributable to shareholders of listed companies
Net profit of recurring profit and loss 2097990883322227860664 – 5.61% 13043350415
Net cash flow from operating activities 3413773652131957301884 6.82% 23160456039
Basic earnings per share (yuan / share) 1.29 1.43 – 9.79% 0.97
Diluted earnings per share (yuan / share) 1.22 1.42 – 14.08% 0.97
Weighted average return on net assets 9.77% – 2.71% – 12.85%
(2) Quarterly main accounting data
